Cidara Therapeutics Stock Price, News & Analysis (NASDAQ:CDTX)

$7.85 0.25 (3.29 %)
(As of 11/17/2017 04:00 PM ET)
Previous Close$7.85
Today's Range$7.88 - $7.70
52-Week Range$5.60 - $11.75
Volume36,145 shs
Average Volume106,170 shs
Market Capitalization$157.86 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Cidara Therapeutics (NASDAQ:CDTX)

Cidara Therapeutics logoCidara Therapeutics, Inc., formerly K2 Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections. Its product portfolio consists of over two formulations of its echinocandin, CD101. CD101 IV is a long-acting therapy for the treatment and prevention of serious, invasive fungal infections. CD101 topical, its second product candidate, is being developed for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC), a prevalent mucosal infection. Its immunotherapy technology platform, Cloudbreak, is used to create compounds designed to direct a patient's immune cells to attack and eliminate pathogens that cause infectious disease. The Company is also developing CD201, its bispecific antimicrobial immunotherapy.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Sector: Bio Therapeutic Drugs
  • Symbol: NASDAQ:CDTX
  • CUSIP: N/A
  • Web: www.cidara.com
Debt:
  • Debt-to-Equity Ratio: 0.16%
  • Current Ratio: 7.69%
  • Quick Ratio: 7.69%
Sales & Book Value:
  • Annual Sales: N/A
  • Price / Sales: N/A
  • Book Value: $2.50 per share
  • Price / Book: 3.14
Profitability:
  • Trailing EPS: ($3.39)
  • Net Income: ($48,160,000.00)
  • Return on Equity: -82.17%
  • Return on Assets: -65.11%
Misc:
  • Employees: 60
  • Outstanding Shares: 20,240,000
 

Frequently Asked Questions for Cidara Therapeutics (NASDAQ:CDTX)

What is Cidara Therapeutics' stock symbol?

Cidara Therapeutics trades on the NASDAQ under the ticker symbol "CDTX."

How were Cidara Therapeutics' earnings last quarter?

Cidara Therapeutics, Inc. (NASDAQ:CDTX) posted its quarterly earnings data on Wednesday, November, 8th. The biotechnology company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.94) by $0.21. View Cidara Therapeutics' Earnings History.

Where is Cidara Therapeutics' stock going? Where will Cidara Therapeutics' stock price be in 2017?

10 brokers have issued 1 year price objectives for Cidara Therapeutics' stock. Their predictions range from $7.25 to $20.00. On average, they anticipate Cidara Therapeutics' share price to reach $13.85 in the next year. View Analyst Ratings for Cidara Therapeutics.

What are Wall Street analysts saying about Cidara Therapeutics stock?

Here are some recent quotes from research analysts about Cidara Therapeutics stock:

  • 1. According to Zacks Investment Research, "Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California. " (10/25/2017)
  • 2. Needham & Company LLC analysts commented, "Cidara mgmt provided a corporate update at an Investor Day in NYC last week and we separately hosted a series of mtgs w/ investors. Mgmt reiterated guidance for top-line results from ongoing Phase 2 trial of CD101 in Invasive Candida infections in 4Q17. The trial is expected to serve as the first of two registration trials. Given discontinuation of CD101 Vulvovaginal Candidiasis program, mgmt introduced plans to instead accelerate development in antifungal prophylaxis. KOLs highlighted differentiation from other echinocandins, w/ emphasis on PK/PD profile and opportunity for better clinical outcomes. New details around Cloudbreak candidates were also announced, although clinical testing not expected until 2018. Stock is attractive ahead of Phase 2 CD101 results later this year (EV $15M)." (4/10/2017)
  • 3. Cantor Fitzgerald analysts commented, "PD/PK Data Points to Success in Phase 2: Presentations reviewed the potency of CD101 against Candida and Aspergillus species as well as broad and sustained tissue distribution. We found the PK/PD optimized dosing data persuasive as it clearly demonstrates, effective AUC/MIC levels at the 400mg once-weekly over three weeks and 400mg loading dose followed by 200mg once weekly for two weeks, paralleling the two dosing regimens being studied in the Phase 2. We also note the potential for subcutaneous dosing, which could enhance the commercial story. We have increased our probability of success from 45% to 50%. Breadth of Cloudbreak Platform Highlighted: In addition to the antibacterial CD201, currently working through pre-IND studies, early in vivo/in vitro data was presented on a new antifungal asset." (4/7/2017)
  • 4. HC Wainwright analysts commented, "This is why there are still no topical echinocandins. Yesterday, before markets opened, Cidara reported results of the Phase 2 RADIANT study in women with vulvovaginal candidiasis (VVC) in which neither topical formulation of CD101 (gel or ointment) achieved efficacy levels comparable to standard of care (SOC) oral fluconazole. As a result, Cidara has discontinued further development of topical CD101 for VVC. The outcome of RADIANT came as a surprise to both management and us, given the potent fungicidal properties of CD101 demonstrated in vitro (even at vaginal pH of 4.0), and that both formulations had outperformed fluconazole in preclinical models' Focus now squarely on STRIVE readout in 4Q17. Recall, STRIVE is a POC Phase 2 candidemia study of CD101 IV vs. Cancidas (IV caspofungin; the leading on-market echinocandin) followed by oral fluconazole step-down (NCT02734862). Coprimary efficacy endpoints are mycological eradication (laboratory cure) and resolution of systemic signs of candidemia (clinical cure)." (2/22/2017)

Who are some of Cidara Therapeutics' key competitors?

Who are Cidara Therapeutics' key executives?

Cidara Therapeutics' management team includes the folowing people:

  • Scott M. Rocklage Ph.D., Chairman of the Board (Age 61)
  • Jeffrey L. Stein Ph.D., President, Chief Executive Officer, Director (Age 62)
  • Matthew W. Onaitis J.D., Chief Financial Officer, Principal Financial Officer, General Counsel, Secretary (Age 45)
  • Kenneth Bartizal Ph.D., Chief Development Officer (Age 63)
  • Paul Daruwala, Chief Commercial Officer (Age 46)
  • Kevin M. Forrest Ph.D., Chief Strategy Officer (Age 39)
  • Taylor Sandison M.D., Chief Medical Officer
  • Daniel D. Burgess, Director (Age 55)
  • Timothy R. Franson M.D., Director (Age 65)
  • Robert J. Perez, Director (Age 52)

When did Cidara Therapeutics IPO?

(CDTX) raised $60 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow Life Sciences, Needham and BTIG were co-managers.

Who owns Cidara Therapeutics stock?

Cidara Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include BB BIOTECH AG (11.05%), JPMorgan Chase & Co. (0.24%), Boothbay Fund Management LLC (0.14%), Raymond James Financial Services Advisors Inc. (0.14%) and OxFORD Asset Management LLP (0.11%). Company insiders that own Cidara Therapeutics stock include Jeffrey Stein, Kevin Forrest, Target N V Biotech and Taylor Sandison. View Institutional Ownership Trends for Cidara Therapeutics.

Who sold Cidara Therapeutics stock? Who is selling Cidara Therapeutics stock?

Cidara Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Boothbay Fund Management LLC. View Insider Buying and Selling for Cidara Therapeutics.

Who bought Cidara Therapeutics stock? Who is buying Cidara Therapeutics stock?

Cidara Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., OxFORD Asset Management LLP and Raymond James Financial Services Advisors Inc.. Company insiders that have bought Cidara Therapeutics stock in the last two years include Jeffrey Stein, Kevin Forrest, Target N V Biotech and Taylor Sandison. View Insider Buying and Selling for Cidara Therapeutics.

How do I buy Cidara Therapeutics stock?

Shares of Cidara Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cidara Therapeutics' stock price today?

One share of Cidara Therapeutics stock can currently be purchased for approximately $7.85.

How big of a company is Cidara Therapeutics?

Cidara Therapeutics has a market capitalization of $157.86 million. The biotechnology company earns ($48,160,000.00) in net income (profit) each year or ($3.39) on an earnings per share basis. Cidara Therapeutics employs 60 workers across the globe.

How can I contact Cidara Therapeutics?

Cidara Therapeutics' mailing address is 6310 Nancy Ridge Dr Ste 101, SAN DIEGO, CA 92121-3209, United States. The biotechnology company can be reached via phone at +1-858-7526170 or via email at [email protected]


MarketBeat Community Rating for Cidara Therapeutics (NASDAQ CDTX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  201 (Vote Outperform)
Underperform Votes:  131 (Vote Underperform)
Total Votes:  332
MarketBeat's community ratings are surveys of what our community members think about Cidara Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Cidara Therapeutics (NASDAQ:CDTX)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 1 Hold Rating, 8 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $13.85 (76.43% upside)

Consensus Price Target History for Cidara Therapeutics (NASDAQ:CDTX)

Price Target History for Cidara Therapeutics (NASDAQ:CDTX)

Analysts' Ratings History for Cidara Therapeutics (NASDAQ:CDTX)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/9/2017HC WainwrightBoost Price TargetBuy$14.00 -> $16.00N/AView Rating Details
9/26/2017Cantor FitzgeraldReiterated RatingBuy$15.00LowView Rating Details
8/11/2017WBB SecuritiesUpgradeSell -> HoldLowView Rating Details
5/16/2017WedbushReiterated RatingOutperform$13.00LowView Rating Details
4/29/2017BTIG ResearchReiterated RatingBuy$15.00 -> $20.00LowView Rating Details
4/20/2017Raymond James Financial, Inc.Initiated CoverageStrong-Buy$14.00HighView Rating Details
4/12/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy -> Buy$11.25LowView Rating Details
4/10/2017Needham & Company LLCReiterated RatingBuy$10.00MediumView Rating Details
3/24/2017Jefferies Group LLCReiterated RatingBuy$15.00HighView Rating Details
12/21/2016Leerink SwannInitiated CoverageOutperform$17.00N/AView Rating Details
(Data available from 11/18/2015 forward)

Earnings

Earnings History and Estimates Chart for Cidara Therapeutics (NASDAQ:CDTX)

Earnings by Quarter for Cidara Therapeutics (NASDAQ:CDTX)

Earnings History by Quarter for Cidara Therapeutics (NASDAQ CDTX)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017Q3 2017($0.94)($0.73)$0.18 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.91)($0.99)$0.25 millionViewN/AView Earnings Details
5/10/2017Q1 2017($0.90)($0.80)ViewN/AView Earnings Details
3/15/2017Q4 2016($0.79)($0.88)ViewN/AView Earnings Details
11/10/2016Q3 2016($0.89)($0.88)ViewN/AView Earnings Details
8/11/2016Q2($0.76)($0.85)ViewN/AView Earnings Details
5/12/2016Q1($0.76)($0.71)ViewN/AView Earnings Details
3/18/2016Q4 2015($0.70)($0.72)ViewN/AView Earnings Details
11/16/2015Q3($0.57)($0.67)ViewListenView Earnings Details
8/11/2015Q2 2015($0.59)($0.59)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cidara Therapeutics (NASDAQ:CDTX)
2017 EPS Consensus Estimate: ($3.45)
2018 EPS Consensus Estimate: ($2.86)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.93)($0.87)($0.90)
Q2 20172($0.89)($0.79)($0.84)
Q3 20172($1.02)($1.01)($1.02)
Q4 20172($0.76)($0.63)($0.70)
Q1 20182($0.78)($0.66)($0.72)
Q2 20182($0.79)($0.50)($0.65)
Q3 20182($0.80)($0.72)($0.76)
Q4 20182($0.87)($0.59)($0.73)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cidara Therapeutics (NASDAQ:CDTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Cidara Therapeutics (NASDAQ CDTX)

Insider Ownership Percentage: 18.90%
Institutional Ownership Percentage: 66.11%
Insider Trades by Quarter for Cidara Therapeutics (NASDAQ:CDTX)
Insider Trades by Quarter for Cidara Therapeutics (NASDAQ:CDTX)

Insider Trades by Quarter for Cidara Therapeutics (NASDAQ CDTX)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/15/2017Target N V BiotechMajor ShareholderBuy60,000$7.57$454,200.00View SEC Filing  
9/12/2017Jeffrey SteinCEOBuy7,350$6.79$49,906.50View SEC Filing  
6/7/2017Taylor SandisonInsiderBuy20,000$5.90$118,000.00View SEC Filing  
6/5/2017Jeffrey SteinCEOBuy15,000$5.95$89,250.00View SEC Filing  
3/31/2017Jeffrey SteinCEOBuy12,900$7.75$99,975.00View SEC Filing  
3/31/2017Kevin ForrestInsiderBuy12,500$7.75$96,875.00View SEC Filing  
5/20/2016Jeffrey SteinCEOBuy4,310$11.51$49,608.10View SEC Filing  
5/20/2016Kevin ForrestCFOBuy4,356$11.53$50,224.68View SEC Filing  
11/25/2015Jeffrey SteinCEOBuy6,700$15.09$101,103.00View SEC Filing  
11/23/2015Kevin ForrestCFOBuy7,087$14.23$100,848.01View SEC Filing  
4/20/2015Timothy R FransonDirectorBuy4,000$16.00$64,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Cidara Therapeutics (NASDAQ:CDTX)

Latest Headlines for Cidara Therapeutics (NASDAQ CDTX)

Source:
DateHeadline
Cidara Therapeutics, Inc. (CDTX) Major Shareholder Target N. V. Biotech Buys 60,000 SharesCidara Therapeutics, Inc. (CDTX) Major Shareholder Target N. V. Biotech Buys 60,000 Shares
www.americanbankingnews.com - November 16 at 4:24 PM
Cidara Therapeutics Named a San Diego Metro Area 2017 Top WorkplaceCidara Therapeutics Named a San Diego Metro Area 2017 Top Workplace
finance.yahoo.com - November 13 at 11:11 PM
Cidara Therapeutics, Inc. (CDTX) Expected to Earn FY2017 Earnings of ($3.14) Per ShareCidara Therapeutics, Inc. (CDTX) Expected to Earn FY2017 Earnings of ($3.14) Per Share
www.americanbankingnews.com - November 13 at 3:58 AM
Cidara Therapeutics, Inc. (CDTX) Forecasted to Earn Q3 2018 Earnings of ($0.72) Per ShareCidara Therapeutics, Inc. (CDTX) Forecasted to Earn Q3 2018 Earnings of ($0.72) Per Share
www.americanbankingnews.com - November 10 at 4:20 PM
Edited Transcript of CDTX earnings conference call or presentation 8-Nov-17 9:05pm GMTEdited Transcript of CDTX earnings conference call or presentation 8-Nov-17 9:05pm GMT
finance.yahoo.com - November 9 at 7:53 PM
Cidara Therapeutics, Inc. (CDTX) Posts  Earnings Results, Beats Expectations By $0.21 EPSCidara Therapeutics, Inc. (CDTX) Posts Earnings Results, Beats Expectations By $0.21 EPS
www.americanbankingnews.com - November 9 at 12:44 AM
5 Biotech Stocks Well Poised to Surpass Expectations in Q35 Biotech Stocks Well Poised to Surpass Expectations in Q3
finance.yahoo.com - November 7 at 8:00 PM
Cidara Therapeutics, Inc. (CDTX) Receives Average Recommendation of "Buy" from BrokeragesCidara Therapeutics, Inc. (CDTX) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - November 6 at 5:48 PM
Cidara Therapeutics to Report Third Quarter 2017 Financial Results and Provide Corporate UpdateCidara Therapeutics to Report Third Quarter 2017 Financial Results and Provide Corporate Update
finance.yahoo.com - November 1 at 5:51 PM
Contrasting ADMA Biologics (ADMA) and Cidara Therapeutics (CDTX)Contrasting ADMA Biologics (ADMA) and Cidara Therapeutics (CDTX)
www.americanbankingnews.com - October 26 at 11:36 AM
Cidara Therapeutics, Inc. (CDTX) Raised to Buy at Zacks Investment ResearchCidara Therapeutics, Inc. (CDTX) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - October 25 at 5:26 PM
QURE On Fast Track, Music To CNCEs Ears, CRBP Gets A Facelift, OBLN DeflatedQURE On Fast Track, Music To CNCE's Ears, CRBP Gets A Facelift, OBLN Deflated
www.rttnews.com - October 19 at 10:36 PM
Cidara Therapeutics (CDTX) Prices $20M Private Placement of Common StockCidara Therapeutics (CDTX) Prices $20M Private Placement of Common Stock
www.streetinsider.com - October 19 at 10:36 PM
Cidara Therapeutics Announces Pricing of $20 Million Private Placement of Common StockCidara Therapeutics Announces Pricing of $20 Million Private Placement of Common Stock
finance.yahoo.com - October 19 at 5:34 PM
Contrasting Spark Therapeutics (ONCE) & Cidara Therapeutics (CDTX)Contrasting Spark Therapeutics (ONCE) & Cidara Therapeutics (CDTX)
www.americanbankingnews.com - October 19 at 12:16 AM
Cidara Therapeutics, Inc. (CDTX) Receives Consensus Rating of "Buy" from AnalystsCidara Therapeutics, Inc. (CDTX) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - October 12 at 6:56 PM
Cidara Therapeutics (CDTX) & Aradigm Corporation (ARDM) Critical AnalysisCidara Therapeutics (CDTX) & Aradigm Corporation (ARDM) Critical Analysis
www.americanbankingnews.com - October 10 at 9:07 AM
Cidara Therapeutics, Inc. (CDTX) Stock Rating Reaffirmed by Cantor FitzgeraldCidara Therapeutics, Inc. (CDTX) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - September 27 at 6:10 PM
Cidara Therapeutics Announces Presentations at IDWeek 2017 and the 8th Trends in Medical Mycology MeetingCidara Therapeutics Announces Presentations at IDWeek 2017 and the 8th Trends in Medical Mycology Meeting
finance.yahoo.com - September 25 at 7:44 PM
Cidara Therapeutics to Present at Two Upcoming ConferencesCidara Therapeutics to Present at Two Upcoming Conferences
finance.yahoo.com - September 18 at 8:37 PM
Cidara Therapeutics, Inc. (CDTX) CEO Acquires $49,906.50 in StockCidara Therapeutics, Inc. (CDTX) CEO Acquires $49,906.50 in Stock
www.americanbankingnews.com - September 12 at 8:24 PM
Cidara Therapeutics to Participate in Keynote Panel Discussion at the 2017 World Antimicrobial Resistance CongressCidara Therapeutics to Participate in Keynote Panel Discussion at the 2017 World Antimicrobial Resistance Congress
finance.yahoo.com - September 7 at 5:09 PM
Antimicrobials Working Group Member Companies Announce Partnership and Exclusive Pricing ProgramAntimicrobials Working Group Member Companies Announce Partnership and Exclusive Pricing Program
www.prnewswire.com - September 6 at 10:05 PM
Cidara Therapeutics, Inc. (CDTX) Short Interest Down 53.3% in AugustCidara Therapeutics, Inc. (CDTX) Short Interest Down 53.3% in August
www.americanbankingnews.com - August 28 at 1:20 AM
Cidara Therapeutics, Inc. (CDTX) Receives Consensus Recommendation of "Buy" from AnalystsCidara Therapeutics, Inc. (CDTX) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - August 23 at 6:46 PM
Brokers Issue Forecasts for Cidara Therapeutics, Inc.s Q3 2017 Earnings (CDTX)Brokers Issue Forecasts for Cidara Therapeutics, Inc.'s Q3 2017 Earnings (CDTX)
www.americanbankingnews.com - August 16 at 7:22 AM
Equities Analysts Offer Predictions for Cidara Therapeutics, Inc.s FY2018 Earnings (CDTX)Equities Analysts Offer Predictions for Cidara Therapeutics, Inc.'s FY2018 Earnings (CDTX)
www.americanbankingnews.com - August 14 at 9:22 AM
Leerink Swann Comments on Cidara Therapeutics, Inc.s Q3 2017 Earnings (NASDAQ:CDTX)Leerink Swann Comments on Cidara Therapeutics, Inc.'s Q3 2017 Earnings (NASDAQ:CDTX)
www.americanbankingnews.com - August 14 at 3:34 AM
Cidara Therapeutics (CDTX) Overweight Rating Reiterated at Cantor FitzgeraldCidara Therapeutics' (CDTX) Overweight Rating Reiterated at Cantor Fitzgerald
www.americanbankingnews.com - August 12 at 6:34 AM
Cidara Therapeutics, Inc. (CDTX) Upgraded to "Hold" at WBB SecuritiesCidara Therapeutics, Inc. (CDTX) Upgraded to "Hold" at WBB Securities
www.americanbankingnews.com - August 11 at 7:32 PM
Cantor Fitzgerald Analysts Give Cidara Therapeutics, Inc. (CDTX) a $15.00 Price TargetCantor Fitzgerald Analysts Give Cidara Therapeutics, Inc. (CDTX) a $15.00 Price Target
www.americanbankingnews.com - August 10 at 6:20 PM
Cidara Therapeutics Inc (NASDAQ:CDTX) Announces Quarterly  Earnings ResultsCidara Therapeutics Inc (NASDAQ:CDTX) Announces Quarterly Earnings Results
www.americanbankingnews.com - August 9 at 11:58 PM
Cidara Therapeutics reports 2Q lossCidara Therapeutics reports 2Q loss
finance.yahoo.com - August 9 at 10:17 PM
Cidara Therapeutics Announces Publication of Results from In Vivo Study Investigating Novel Antifungal CD101 in Intra-Abdominal Candidiasis (IAC)Cidara Therapeutics Announces Publication of Results from In Vivo Study Investigating Novel Antifungal CD101 in Intra-Abdominal Candidiasis (IAC)
finance.yahoo.com - August 1 at 3:34 PM
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Given Average Recommendation of "Buy" by AnalystsCidara Therapeutics, Inc. (NASDAQ:CDTX) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - July 29 at 4:43 PM
Cidara Therapeutics to Participate in Anti-Infectives Panel Discussion at the 2017 Infectious Diseases SummitCidara Therapeutics to Participate in Anti-Infectives Panel Discussion at the 2017 Infectious Diseases Summit
finance.yahoo.com - July 6 at 6:16 PM
Cidara Therapeutics, Inc. (CDTX) Given Average Rating of "Buy" by BrokeragesCidara Therapeutics, Inc. (CDTX) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 4 at 5:22 PM
CIDARA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive AgreementCIDARA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
biz.yahoo.com - March 31 at 9:23 PM
Cidara Therapeutics (CDTX) Secures $6.9M Grant from CARB-XCidara Therapeutics (CDTX) Secures $6.9M Grant from CARB-X
www.streetinsider.com - March 31 at 2:39 AM
Cidara Therapeutics Awarded $6.9 Million Grant from CARB-X to Advance Development of its First CloudbreakTM Antibiotic ImmunotherapyCidara Therapeutics Awarded $6.9 Million Grant from CARB-X to Advance Development of its First CloudbreakTM Antibiotic Immunotherapy
us.rd.yahoo.com - March 30 at 4:38 PM
Cidara Therapeutics upgraded by WBB SecuritiesCidara Therapeutics upgraded by WBB Securities
us.rd.yahoo.com - February 23 at 4:11 PM
Cidara Yeast Infection Gelm Fails Phase 2 TrialCidara Yeast Infection Gelm Fails Phase 2 Trial
us.rd.yahoo.com - February 23 at 4:11 PM
Cidara Therapeutics (CDTX) Says Phase 2 RADIANT Trial of CD101 Didnt Show Sufficient EfficacyCidara Therapeutics (CDTX) Says Phase 2 RADIANT Trial of CD101 Didn't Show Sufficient Efficacy
www.streetinsider.com - February 22 at 12:11 PM
Cidara Yeast Infection Gel Fails Phase 2 (CDTX)Cidara Yeast Infection Gel Fails Phase 2 (CDTX)
www.investopedia.com - February 22 at 12:11 PM
CIDARA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and ExhibiCIDARA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibi
biz.yahoo.com - February 21 at 2:26 PM
8:32 am Cidara Therapeutics announces data from preclinical and clinical studies evaluating its novel echinocandin antifungal CD101 in the journal Antimicrobial Agents and Chemotherapy8:32 am Cidara Therapeutics announces data from preclinical and clinical studies evaluating its novel echinocandin antifungal CD101 in the journal Antimicrobial Agents and Chemotherapy
us.rd.yahoo.com - December 15 at 3:14 AM
Cidara Provides Corporate Update and Reports Third Quarter 2016 Financial ResultsCidara Provides Corporate Update and Reports Third Quarter 2016 Financial Results
www.nasdaq.com - November 10 at 10:11 PM
Cidara Therapeutics Announces Data from Studies of Novel Antifungal CD101 to be Presented at ACCP and IDWeek Annual MeetingsCidara Therapeutics Announces Data from Studies of Novel Antifungal CD101 to be Presented at ACCP and IDWeek Annual Meetings
www.businesswire.com - October 25 at 8:59 AM
Cidara Therapeutics (CDTX) Prices 2.48M Common Stock Offering at $10.10/ShareCidara Therapeutics (CDTX) Prices 2.48M Common Stock Offering at $10.10/Share
www.streetinsider.com - October 8 at 8:52 AM
CIDARA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial StaCIDARA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Sta
biz.yahoo.com - October 8 at 8:52 AM

Social Media

Financials

Chart

Cidara Therapeutics (NASDAQ CDTX) Chart for Saturday, November, 18, 2017
Loading chart…

This page was last updated on 11/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.